BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
9.09
-0.04 (-0.44%)
Mar 13, 2026, 4:00 PM EDT - Market closed

BBOT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
24.627.760.040
Research & Development
121.273.11--
Total Operating Expenses
145.8280.860.040
Operating Income
-145.82-80.86-0.04-0
Interest Income
11.346.38--
Other Non-Operating Income (Expense)
0.430.21--
Total Non-Operating Income (Expense)
11.786.59--
Pretax Income
-134.04-74.28-0.04-0
Net Income
-134.04-74.28-0.04-0
Net Income to Common
-134.04-74.28-0.04-0
Shares Outstanding (Basic)
31044
Shares Outstanding (Diluted)
31044
Shares Change (YoY)
241276.23%-99.66%--
EPS (Basic)
-4.30-5756.41-0.01-
EPS (Diluted)
-4.30-5756.41-0.01-
Free Cash Flow
-114.5-55.0800
Free Cash Flow Per Share
-3.68-4268.46--
EBITDA
-145.21-80.66-0.04-0
EBIT
-145.82-80.86-0.04-0
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.